Aristides Capital’s Regenxbio RGNX Stock Holding History

Aristides Capital’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-24,200	Closed	-$187K	–	318
2024 Q4	$187K	Buy	+24,200	New	+$227K	0.04%	254

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Aristides Capital's RGNX Position: Q1 2025 in Review

Aristides Capital sold out of Regenxbio (RGNX) in Q1 2025, closing a stake of 24,200 shares — an estimated $187K sold.

Aristides Capital first reported a position in RGNX in Q4 2024 and held it in 1 quarter. The position peaked at $187K in Q4 2024. 164 funds tracked by Wall St. Rank hold RGNX as of Q1 2025.

Aristides Capital reported no remaining Regenxbio position as of Q1 2025 after selling out during the quarter.
Aristides Capital sold 24,200 Regenxbio shares in Q1 2025, an estimated $187K.
Aristides Capital first reported a position in Regenxbio in Q4 2024 and held it in 1 quarter.
Aristides Capital's Regenxbio position peaked at $187K in Q4 2024.
164 funds tracked by Wall St. Rank held Regenxbio as of Q1 2025.

Based on Aristides Capital's 13F filing for Q1 2025, filed 14 May 2025.